Can tirzepatide cause insomnia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 3, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Insomnia is Not a Recognized Side Effect of Tirzepatide Based on Current Guidelines

Insomnia is not listed among the common or documented side effects of tirzepatide in the most recent clinical guidelines and FDA-approved prescribing information. The most common adverse effects are gastrointestinal in nature—nausea, vomiting, and diarrhea—occurring primarily during dose escalation 1.

Documented Side Effect Profile

According to the 2025 American Association of Clinical Endocrinology consensus statement, the established side effects of tirzepatide and other GLP-1 receptor agonist-based medications include 1:

  • Gastrointestinal effects (most common): nausea, vomiting, diarrhea, occurring especially during dose escalation
  • Cardiovascular: modest increase in heart rate
  • Metabolic complications: increased risk of gallbladder/biliary disease
  • Laboratory changes: elevations in lipase and amylase without pancreatitis
  • Dehydration risk: particularly with vomiting or diarrhea, requiring monitoring for renal impairment

The FDA recommends monitoring for mood changes, emerging or worsening depression, or suicidal behavior, though evidence is insufficient to support a causal association 1.

Emerging Research Signal

However, one very recent 2026 observational study suggests a potential association. In a large U.S. electronic health record analysis comparing tirzepatide to semaglutide in adults without type 2 diabetes, tirzepatide was associated with a higher hazard of insomnia (HR 1.13,95% CI 1.05-1.21) 2. This finding:

  • Comes from observational data subject to residual confounding and diagnosis misclassification
  • Has not been incorporated into clinical guidelines or FDA labeling
  • Represents a modest increase in relative terms
  • Requires confirmation in prospective studies

Clinical Implications

For practical management:

  • Insomnia should not be expected as a typical side effect when counseling patients starting tirzepatide
  • If insomnia develops after initiating tirzepatide, consider other contributing factors first (weight loss effects, dietary changes, concurrent medications, underlying sleep disorders)
  • The observational signal is insufficient to alter prescribing decisions but may warrant monitoring
  • Document any sleep disturbances that emerge during treatment

Common pitfall: Attributing all new symptoms to a recently started medication without considering the broader clinical context, including the metabolic improvements and lifestyle changes that accompany significant weight loss.

The established benefit-risk profile of tirzepatide remains strongly favorable, with documented improvements in weight, glycemic control, and even obstructive sleep apnea 1, 3, 4, making any potential insomnia signal a minor consideration in the overall therapeutic decision.

References

1
Guideline

american association of clinical endocrinology consensus statement: algorithm for the evaluation and treatment of adults with obesity/adiposity-based chronic disease - 2025 update.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2025

3
Research

Association of tirzepatide with changes in OSA-related measures based on baseline characteristics - post hoc analyses of SURMOUNT-OSA.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2026

4
Research

Beyond weight loss: tirzepatide as a dual GIP/GLP-1 receptor agonist for obstructive sleep apnea.

Current opinion in endocrinology, diabetes, and obesity, 2026

Related Questions

What is the recommended Zepbound (tirzepatide) dosing for adults with moderate-to-severe obstructive sleep apnea and obesity?
What evidence supports the use of tirzepatide (a dual GLP‑1/GIP receptor agonist) for improving fertility?
In a 76-year-old female, 4 ft 10 in, weighing 225 lb, with a shortened torso from early spinal surgery, chronic exertional dyspnea requiring continuous supplemental oxygen, sleep apnea managed with CPAP, borderline non‑alcoholic fatty liver disease, a history of constipation, low‑protein diet, and risk of sarcopenia, would initiating tirzepatide (Mounjaro) provide a net benefit or net disadvantage for alleviating her shortness of breath considering its gastrointestinal side effects and potential muscle loss?
Are GLP‑1 receptor agonists (GLP‑1 RAs) FDA‑approved for treating obstructive sleep apnea (OSA)?
Does tirzepatide (GLP‑1/GIP receptor agonist) interact with Veozah (fezolinetant)?
In a 72-year-old man with impaired renal function (serum creatinine 2.03 mg/dL) who was on allopurinol 50 mg and completed a 5‑day course of prednisone 40 mg for an acute gout flare that has now resolved, should the allopurinol dose be increased?
How can I use and interpret the zero‑volume (0 V) loop on a ventilator to assess trigger and cycling settings?
With nighttime basal insulin and a pre‑breakfast capillary blood glucose of 125 mg/dL, is additional pre‑breakfast insulin indicated?
How does chronic alcohol consumption affect CD8-positive T-cell counts, and what evaluation and management should be done for alcoholic patients?
In a 25‑year‑old male with severe neurogenic orthostatic hypotension, low renin and aldosterone, non‑length‑dependent small‑fiber loss on thigh skin biopsy, and new ulcerative colitis, what evidence (with citations and grading) exists regarding the time course and frequency of phenelzine‑induced orthostatic hypotension, its ability to produce the observed selective adrenergic failure, the selectivity and prevalence of seronegative autoimmune autonomic ganglionopathy (including its association with inflammatory bowel disease), the role of pyridoxine toxicity in causing non‑length‑dependent neuropathy and autonomic dysfunction, which tests can differentiate drug‑induced effects from true ganglionic failure while the patient remains on his current medications, whether any of his medications (phenelzine, lithium, ketamine, pregabalin, botulinum toxin) can explain low renin/aldosterone, and whether it is reasonable to ask Mayo Clinic to reconsider the diagnosis before initiating a 12‑week IVIG trial?
Is sildenafil the same as tadalafil?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.